Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Renaissance Technologies LLC

Renaissance Technologies LLC boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 27.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 5,329,743 shares of the biopharmaceutical company's stock after acquiring an additional 1,141,219 shares during the period. Gilead Sciences comprises approximately 0.7% of Renaissance Technologies LLC's holdings, making the stock its 10th biggest holding. Renaissance Technologies LLC owned 0.43% of Gilead Sciences worth $492,308,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. HHM Wealth Advisors LLC grew its holdings in Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 154 shares during the period. YANKCOM Partnership acquired a new stake in shares of Gilead Sciences during the 4th quarter worth $28,000. Decker Retirement Planning Inc. purchased a new position in shares of Gilead Sciences in the 4th quarter worth $29,000. Crews Bank & Trust acquired a new position in Gilead Sciences in the fourth quarter valued at $31,000. Finally, Stephens Consulting LLC grew its position in Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 260 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares of the company's stock, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last quarter, insiders sold 302,785 shares of company stock worth $30,503,250. 0.16% of the stock is owned by company insiders.

Remove Ads

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Wells Fargo & Company lifted their price target on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Oppenheimer increased their price objective on shares of Gilead Sciences from $115.00 to $132.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 4th. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and lifted their target price for the company from $80.00 to $120.00 in a report on Tuesday, February 18th. Finally, Bank of America increased their price target on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a report on Wednesday, March 5th. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $105.12.

Gilead Sciences Stock Performance

NASDAQ:GILD traded up $2.23 during midday trading on Friday, reaching $103.63. 8,683,683 shares of the company traded hands, compared to its average volume of 7,493,897. The firm has a market capitalization of $129.04 billion, a price-to-earnings ratio of 280.08, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32. The company has a fifty day moving average price of $108.34 and a 200 day moving average price of $96.79. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were paid a dividend of $0.79 per share. The ex-dividend date was Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 3.05%. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's payout ratio is presently 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.